Abstract
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective and safe oral incretin-based antihyperglycemic drugs. In preclinical studies, DPP-4 inhibitors have demonstrated cardiovascular benefits, independent of glycemic control, in patients with type-2 diabetes mellitus. Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Since 2013, alogliptin is the 4th approved DPP-4 inhibitor available on the market. Studies have shown that alogliptinis non-inferior to comparator drugs among newly diagnosed type 2 diabetes mellitus patients. Alogliptin can effectively be used as a single agent or as an add-on drug in combination with other glucose lowering drugs with favorable outcomes on glycemic control and HbA1C levels.
Keywords: Alogliptin, antihyperglycemic agents, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1, glucosedependent insulinotropic peptide, incretins, type 2 diabetes mellitus.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Volume: 14 Issue: 1
Author(s): Sarmad Said, Azikiwe C. Nwosu, Debabrata Mukherjee and German T. Hernandez
Affiliation:
Keywords: Alogliptin, antihyperglycemic agents, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1, glucosedependent insulinotropic peptide, incretins, type 2 diabetes mellitus.
Abstract: Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective and safe oral incretin-based antihyperglycemic drugs. In preclinical studies, DPP-4 inhibitors have demonstrated cardiovascular benefits, independent of glycemic control, in patients with type-2 diabetes mellitus. Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Since 2013, alogliptin is the 4th approved DPP-4 inhibitor available on the market. Studies have shown that alogliptinis non-inferior to comparator drugs among newly diagnosed type 2 diabetes mellitus patients. Alogliptin can effectively be used as a single agent or as an add-on drug in combination with other glucose lowering drugs with favorable outcomes on glycemic control and HbA1C levels.
Export Options
About this article
Cite this article as:
Said Sarmad, Nwosu C. Azikiwe, Mukherjee Debabrata and Hernandez T. German, Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X14666140701095849
DOI https://dx.doi.org/10.2174/1871529X14666140701095849 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nmr Studies Of The Prionogenic Peptide Derived From Sup35 Protein
Protein & Peptide Letters Antidyslipidemic Capacity of <i>Cleome arabica</i> (L.) in Streptozotocin-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Trends in Utilization of the Pharmacological Potential of Chalcones
Current Clinical Pharmacology Are Major Depressive Disorder and Diabetes Mellitus Amyloidogenic Conditions?
CNS & Neurological Disorders - Drug Targets DNA Damage and Epigenetic Changes in Kidney Diseases - Focused on Transcription Factors in Podocytes
Current Hypertension Reviews New Insight into the Mechanisms of <i>Ginkgo Biloba</i> Extract in Vascular Aging Prevention
Current Vascular Pharmacology Biphasic (Premix) Insulin Analogs in Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antihypertensive Drug Treatment and Circadian Blood Pressure Rhythm: A Review of the Role of Chronotherapy in Hypertension
Current Pharmaceutical Design Innate Immunity, Toll-Like Receptors, and Diabetes
Current Immunology Reviews (Discontinued) Myocardial Infarction. Pathological Relevance and Relationship with Coronary Risk Factors
Current Pharmaceutical Design Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design L-Arginine in the Prevention and Treatment of Cardiovascular Disease: From Basic to Clinical Research Studies
Vascular Disease Prevention (Discontinued) Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry Giant Cell Arteritis – A Series of Cases and Review of Literature
Current Rheumatology Reviews Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry An Overview of the Modulatory Effects of Oleic Acid in Health and Disease
Mini-Reviews in Medicinal Chemistry Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews Docking Study of Novel Pyrrolidine Derivatives as Potential Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors
Letters in Drug Design & Discovery Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy